32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences Set to Attend the 2026 JPM Healthcare Conference
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences Joins Featured Startups in the Midwest Biotech Startup Showcase
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences receives $6 million in funding to advance gut microbiome platform technologies
32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones.
32 Biosciences Raises $6M, Advances Gut Microbiome Diagnostics Toward FDA Clearance
Chicago-based biotech exceeds fundraising goals while building leadership team for regulatory milestones
Chicago startup 32 Biosciences raises $6 million, eyes FDA approval next
A Chicago-based biotech startup is making waves in the gut health industry, securing millions in funding to advance its innovative microbiome tools.
32 Biosciences Surpasses Financing Target, Accelerates Toward Series A and FDA Milestones
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
Microbiota-dependent Early-life Programming of Gastrointestinal Motility
Gastrointestinal microbes modulate peristalsis and stimulate the enteric nervous system (ENS), whose development, as in the central nervous system (CNS), continues into the murine postweaning period.Given that adult CNS function depends on stimuli received during critical periods of postnatal development, we hypothesized that adult ENS function, namely motility, depends on microbial stimuli during similar critical […]
UChicago Microbiome Startups Come Together Under New Company to Amplify Results
Two University of Chicago startups are now operating under a parent company, 32 Biosciences – with a shared goal to revolutionize health care through advances in microbiome science. The name is pronounced “three squared biosciences” in homage to its three scientific founders and microbiome medicine experts: University of Chicago professors John Alverdy and Eugene Chang, and assistant professor […]
2 UChicago Gut Science Startups Form New Entity
